1,3-Dihydroxy-naphthalin-carbonsaeure-(2)-amid | 99972-58-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,3-Dihydroxy-naphthalin-carbonsaeure-(2)-amid
• 英文别名: 1,3-dihydroxy-[2]naphthoic acid amide；1,3-Dihydroxy-[2]naphthoesaeure-amid；1,3-Dihydroxynaphthalene-2-carboxamide；1,3-dihydroxynaphthalene-2-carboxamide
• CAS: 99972-58-4
• 化学式: C₁₁H₉NO₃
• 分子量: 203.197
• InChiKey: DDWKTDZDDBPJOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,3-Dihydroxy-naphthalin-carbonsaeure-(2)-amid 在 吡啶 、 sodium hydroxide 、 丙酮 作用下， 生成 1,3-dihydroxy-[2]naphthoic acid acetylamide
  参考文献：
  名称：

  Bretschneider; Rogenhofer, Monatshefte fur Chemie, 1957, vol. 88, p. 652,661

  摘要：

  DOI：
• 作为产物：
  描述：

  1,3-二羟基萘-2-甲酸乙酯 在 氨 作用下， 生成 1,3-Dihydroxy-naphthalin-carbonsaeure-(2)-amid
  参考文献：
  名称：

  Bretschneider; Rogenhofer, Monatshefte fur Chemie, 1957, vol. 88, p. 652,661

  摘要：

  DOI：

文献信息

• Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
  申请人：EPIZYME, INC.

  公开号：US10266526B2

  公开（公告）日：2019-04-23

  The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.

  本公开提供了具有式（I）的羧酰胺类和磺酰胺类化合物：及其药学上可接受的盐和溶剂，其中A、Y、B、X和Z的定义如说明书所述。本公开还涉及使用式（I）化合物治疗对 SMYD 蛋白如 SMYD3 或 SMYD2 的阻断有反应的紊乱。本公开的化合物尤其适用于治疗癌症。
• Budesinsky; Svab, Collection of Czechoslovak Chemical Communications, 1958, vol. 23, p. 1066,1068
  作者：Budesinsky、Svab

  DOI：——

  日期：——
• SMYD Inhibitors
  申请人：EPIZYME, INC.

  公开号：US20170355695A1

  公开（公告）日：2017-12-14

  The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
• SMYD INHIBITORS
  申请人：EPIZYME, INC.

  公开号：US20190322660A1

  公开（公告）日：2019-10-24

  The present disclosure provides carboxamides and sulfonamides having Formula (I): and the pharmacentically acceptable salts and solvates thereof, wherein A, Y, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
• Bretschneider; Rogenhofer, Monatshefte fur Chemie, 1957, vol. 88, p. 652,661
  作者：Bretschneider、Rogenhofer

  DOI：——

  日期：——